New hope for kidney transplant patients: frexalimab vs standard care
NCT ID NCT07412470
First seen Feb 19, 2026 · Last updated Apr 29, 2026 · Updated 4 times
Summary
This study tests whether a new drug called frexalimab works better than the standard drug tacrolimus at preventing kidney transplant rejection. About 526 adults receiving their first kidney transplant will be followed for up to 5 years. The goal is to see if frexalimab can reduce rejection, graft loss, and death while being safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT REJECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational Site Number : 0360003
RECRUITINGSydney, 2050, Australia
-
Investigational Site Number : 1560001
RECRUITINGShanghai, 200127, China
-
Investigational Site Number : 1560003
RECRUITINGChengdu, 610041, China
-
Investigational Site Number : 1560006
RECRUITINGWuhan, 430030, China
-
Investigational Site Number : 1560017
RECRUITINGNanchang, 330006, China
-
Investigational Site Number : 2080001
RECRUITINGAarhus, 8200, Denmark
-
Investigational Site Number : 7240001
RECRUITINGBarcelona, Barcelona [Barcelona], 08035, Spain
-
Investigational Site Number : 7240003
RECRUITINGL'Hospitalet de Llobregat, Catalunya [Cataluña], 08907, Spain
-
Investigational Site Number : 7240005
RECRUITINGMálaga, 29010, Spain
-
Investigational Site Number : 8260001
RECRUITINGBirmingham, England, B15 2TH, United Kingdom
Conditions
Explore the condition pages connected to this study.